AI summary by TwinMind

Rick Doblin: Psychedelics | Lex Fridman Podcast #202

Lex Fridman

2h 36m 6s

Introduction to Psychedelics and MAPS

  • Rick Doblin - founder/executive director of MAPS (Multidisciplinary Association for Psychedelic Studies)
  • Psychedelic means "mind manifesting" - coined by Humphrey Osmond in dialogue with Aldous Huxley
  • MAPS interprets psychedelic broadly: dreams, holotropic breathwork, hyperventilation, meditation
  • Primary focus on drugs/medicines/spiritual tools/sacraments

Categories of Psychedelics

  • Classic psychedelics: ego-dissolving, unitive states
    • LSD, psilocybin, mescaline, ayahuasca, ibogaine, DMT
  • MDMA: empathogen/entactogen - "touching within" or empathy
    • Doesn't cause same ego dissolution as classics
    • Brings material to surface, changes processing
  • Marijuana: closer to classic psychedelics than MDMA
  • Dreams as natural psychedelic state - everyone can relate

Mechanism: Bringing Things to Surface

  • Brain as "reducing valve" (Aldous Huxley concept)
  • Mind filters enormous information input, focuses on core needs (Maslow's hierarchy)
  • Psychedelics dissolve ego control or strengthen self-acceptance (MDMA)
  • Reveal suppressed material: traumas, conflicts, difficult emotions
  • Not conjuring new experiences - revealing what's already within
  • Sasha Shulgin: "having human experience that mescaline helps access" vs "mescaline experience"

Collective Unconscious and Memory

  • Jungian collective unconscious - accessing information beyond personal temporal existence
  • Wave resonances allowing access to other times/places through emotional resonances
  • Holographic reality concept
  • Cultural transmission more determinative than often credited
  • Example: Terence McKenna's "machine elves" as cultural construct vs universal experience

Differences Between Psychedelics

Duration and Administration

  • DMT (smoked): 10-15 minutes, rapid onset
  • 5-MeO-DMT: very rapid when smoked
  • Ayahuasca (oral DMT): couple hours
  • LSD: 8-12 hours
  • Psilocybin: 4-6 hours
  • MDMA: similar to psilocybin, supplemental dosing used in research

Chemical Structure and Effects

  • Mescaline: chemically most similar to MDMA (phenethylamine)
  • Has warmth of MDMA, less ego-dissolving than other classics
  • 1953 Army Chemical Warfare study: methamphetamine to mescaline spectrum, MDMA in middle

Religious/Cultural Context

  • Some have thousands of years religious use (psilocybin mushrooms)
  • Eleusinian Mysteries (1600 BC - 396 AD): longest mystery ceremonies, LSD-like substance
  • 5-MeO-DMT claims of indigenous use are modern fabrications
  • Rise of for-profit companies researching all types

Future Engineering of Psychedelics

  • Buckminster Fuller prediction: technology miniaturization → telepathy
  • Stan Grof's wife Brigitta: MDMA + 5-MeO-DMT combination
    • Ego dissolution with underlying sense of safety/self-acceptance
  • Personalized sequences of different drugs over time
  • Structure-activity relationships still mysterious
  • Sasha Shulgin's methodology: self-experimentation → wife → 12-person group → Leo Zeff (therapeutic use)

Historical Context: MK Ultra and Ken Kesey

  • CIA program weaponizing psychedelics for interrogation, mind control
  • Dosing people without consent, violating human rights
  • Ken Kesey participated, later inspired hippie opposition to Vietnam War
  • Unintended consequence: Grateful Dead emerged from acid tests
  • Ted Kaczynski (Unabomber) allegedly part of MK Ultra at Harvard
  • Context determines outcome - same drugs, different results

Timothy Leary and Harvard Research

  • Nixon called him "most dangerous man in America"
  • "Think for yourself, question authority"
  • Harvard research 1960-1963: Good Friday Experiment, Concord Prison Experiment
  • Good Friday: psilocybin in religious setting to produce mystical experience
  • Concord Prison: reduce recidivism through mystical experiences
  • Later revealed data manipulation in prison study
  • Leary's approach: over-promised benefits, under-stated risks
  • "Fuck the government... but I'm glad you're doing it" (to Rick)

MAPS Formation and Strategy (1986)

  • Created after DEA criminalized MDMA in 1985
  • Non-profit pharmaceutical company - first of its kind
  • Strategy: Americans open to medicines for suffering
  • Mission: mass mental health, spiritualizing humanity
  • Einstein quote: "splitting of atom changed everything except mode of thinking"
  • Two tracks: drug development + drug policy reform

MAPS Structure Evolution

  • 2014: Created MAPS Public Benefit Corporation
  • Non-profit owns 100% of pharma company
  • Benefit corporation maximizes public benefit, not profit
  • Data exclusivity (5-6 years) provides revenue stream
  • Boston Consulting Group projects ~$750M profits during exclusivity period
  • 130 employees: 1/3 non-profit (harm reduction, education), 2/3 benefit corp (research)

Phase Development Process

  • Pre-clinical: Animal safety studies
  • Phase 1: First human studies, safety in healthy volunteers
  • Phase 2: Patient studies, design Phase 3, determine risks/benefits/measures
  • Phase 3: Large-scale, multi-site, placebo-controlled studies proving safety/efficacy

Double-Blind Problem

  • Classic challenge: psychedelics have obvious effects, hard to blind
  • Rick's dissertation solution: low-dose vs full-dose MDMA
  • Discovery: 75mg was effective dose (lower than expected 125mg)
  • Low doses (25-50mg) created "anti-therapeutic effect" - stimulation without fear reduction
  • FDA accepted therapy + inactive placebo vs therapy + full-dose MDMA design
  • Independent rater pool of 20+ calibrated evaluators

Phase 3 PTSD Study Results (Nature Medicine, May 2021)

Study Design

  • 90 participants (46 MDMA, 44 placebo)
  • Chronic, severe PTSD patients
  • Included previous suicide attempts (typically excluded)
  • 15 sites (2 Israel, 2 Canada, 11 US)
  • ~80 therapists trained

Statistical Results

  • P-value: 0.0001 (1 in 10,000 chance of random result)
  • Effect size: 0.91 placebo-subtracted, 2.1 within-group
  • No effect by site (consistent across all locations)
  • 67% MDMA group no longer had PTSD vs 32% placebo group at 2 months

Safety Findings

  • Two suicide attempts during study - both in placebo group
  • No suicide attempts in MDMA group
  • Side effects: transitory, minor (sweating, jaw clenching, slight temperature increase)
  • No neurocognitive decline
  • Dissociative subtype (hardest to treat) did even better with MDMA

Mechanism

  • MDMA reduces amygdala activity (fear processing)
  • Increases prefrontal cortex activity (logical thinking)
  • Increases connectivity between amygdala and hippocampus
  • Enhances memory for trauma while reducing fear
  • Helps process memories into long-term storage (past vs always about to happen)

Timeline for Access

  • End of 2023: FDA approval expected for MDMA-assisted therapy for PTSD
  • Expanded access: 50 people approved for compassionate use (starting ~2 months from interview)
  • Off-label prescription: Doctors can prescribe for other conditions once approved
  • 2035: Licensed legalization for personal growth predicted
  • Decade of clinics: Thousands of psychedelic clinics rolling out post-approval

Other Promising Applications

  • Psilocybin: Life-threatening illness, addiction, depression (breakthrough therapy status)
  • Ibogaine: Opiate addiction, withdrawal management
  • MDMA: Alcohol use disorder (Ben Sessa's research)
  • Trauma underlying addiction: Common thread across substances
  • Revolution in psychiatry predicted - returning therapists to treating individuals vs just prescribing

For-Profit Company Concerns

  • Rise indicates success but creates profit maximization pressure
  • Risk: minimizing therapy to reduce costs
  • S-ketamine example: approved without therapy, results fade quickly
  • Ketamine clinics discovering therapy improves outcomes
  • Generic ketamine vs expensive S-ketamine
  • MAPS leading by example with benefit corporation model

Advice to Young People

  • Find combination of what world needs + what you need for survival
  • Howard Thurman quote: "Find what makes you come alive - world needs people who have come alive"
  • Beware trap of needing vast resources
  • Separate happiness from accomplishments - focus on effort
  • Build long-term relationships across perceived divides
  • Be persistent - "once FDA/DEA figured out we're not going anywhere, progress started"
  • 20-year plans not really that long

Philosophical Insights

  • Don't need answers to big "why" questions
  • Grateful for death - makes life precious
  • Parents' quote: "Make up for brevity of life with intensity of life"
  • One life is enough
  • We're social creatures - making others happy, being made happy sufficient meaning
  • Humanity in everyone - avoid us vs them thinking
  • Example: Training police officer as MDMA therapist

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome